Get access

CyclinD1, p53, E-cadherin, and VEGF discordant expression in paired regional metastatic lymph nodes of esophageal squamous cell carcinoma: A tissue array analysis

Authors

  • Kong-Jia Luo MD,

    1. State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
    2. Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
    Search for more papers by this author
  • Yi Hu MD, PhD,

    1. Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
    Search for more papers by this author
  • Jing Wen MD,

    1. Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
    Search for more papers by this author
  • Jian-Hua Fu MD, PhD

    Corresponding author
    1. Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
    • Department of Thoracic Oncology, Cancer Center, Sun Yat-Sen University, 651 Dong Feng Road East, Guangzhou 510060, People's Republic of China. Fax: +86-20-87343638.
    Search for more papers by this author

  • Kong-Jia Luo and Yi Hu contributed equally to this work.

  • There were no financial disclosures, conflicts of interest and acknowledgments in our research.

Abstract

Background and Objectives

The correlation of biomarker expression between primary tumors and corresponding metastases has not yet been well reported in esophageal squamous cell carcinoma (ESCC). This study was to confirm whether primary ESCC tumors differ from their regional metastatic lymph nodes (RMLN) in CyclinD1, p53, E-cadherin, and vascular endothelial growth factor (VEGF) expression and determine prognostic value of their alteration.

Methods

There were 134 patients with stage T3N1-3M0 ESCC recruited for the research. Expression of CyclinD1, p53, E-cadherin, and VEGF was evaluated in primary ESCC tumors and their paired RMLN assembled on tissue microarrays by immunohistochemistry (IHC). The comparison of expression in different lesion and their correlation with prognosis was analyzed.

Results

E-cadherin was discordant expression in 55.2% cases and appeared to be more frequently positive in metastatic lymph nodes (P < 0.001). The VEGF expression level was significantly higher in primary tumors (P < 0.001). Combined analysis of VEGF expressions in paired lesions (P = 0.003) and its decreased expression (P = 0.006) were both predictive.

Conclusions

Biomarker expression was discordant between the primary tumor and its paired lymphatic metastasis in over 25% of patient with ESCC. VEGF discordant expression was a new prognostic factor and combined analysis of expression in paired lesions was useful to predict. Analysis of protein expression only in primary tumors would be inadequate to judge prognosis. J. Surg. Oncol. 2011; 104:236–243. © 2011 Wiley-Liss, Inc.

Ancillary